On March 30, 2023, the Supreme Court of Canada dismissed Pharmascience’s application for leave to appeal (Docket No. 40400) a decision of the Federal Court of Appeal (FCA) upholding the validity of two patents relating to apixaban (Bristol-Myers Squibb’s ELIQUIS). The FCA had dismissed Pharmascience’s appeal of a Federal Court decision upholding the validity of Canadian Patent Nos. 2,461,202 (apixaban and uses thereof in the treatment of thromboembolic disorders) and 2,791,171 (tablet formulations of apixaban) (see previously reported “Federal Court of Appeal upholds validity of two patents relating to ELIQUIS”).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.